Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114972363 | 11497236 | 3 | F | 20150211 | 20160805 | 20150911 | 20160812 | EXP | US-PFIZER INC-2015297013 | PFIZER | 14.00 | YR | F | Y | 53.00000 | KG | 20160812 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 114972363 | 11497236 | 1 | PS | CRIZOTINIB | CRIZOTINIB | 1 | Oral | COURSE A, B: 165MG/M2, BID ON DAYS 1-21 | U | 202570 | 165 | MG/M**2 | BID | ||||||
| 114972363 | 11497236 | 2 | SS | DOXORUBICIN HCL | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | COURSE B: 25 MG/M2, OVER 1-15 MIN ON DAYS 4 AND 5 | U | 50467 | 25 | MG/M**2 | |||||||
| 114972363 | 11497236 | 3 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intrathecal | PROPHASE: 7.5-12MG IT ON DAY 1 | U | 11719 | |||||||||
| 114972363 | 11497236 | 4 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intravenous (not otherwise specified) | COURSE A: 3000 MG/M2, OVER 3 HOURS ON DAY 1 | U | 11719 | 3000 | MG/M**2 | |||||||
| 114972363 | 11497236 | 5 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intravenous (not otherwise specified) | COURSE B: 3000 MG/M2, OVER 3 HOURS ON DAY 1 | U | 11719 | 3000 | MG/M**2 | |||||||
| 114972363 | 11497236 | 6 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | PROPHASE: 200 MG/M2, IV OVER 15-30 MINUTES ON DAYS 1 AND 2 | U | 0 | 200 | MG/M**2 | |||||||
| 114972363 | 11497236 | 7 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | COURSE B: 200MG/M2, IV OVER 15-30 MINUTES ON DAYS 1-5 | U | 0 | 200 | MG/M**2 | |||||||
| 114972363 | 11497236 | 8 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | PROPHASE: 5 MG/M2, QD ON DAYS 1-2 AND BID ON DAYS 3-5 | U | 0 | 5 | MG/M**2 | |||||||
| 114972363 | 11497236 | 9 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | COURSE A: 5 MG/M2, BID ON DAYS 1-5 | U | 0 | 5 | MG/M**2 | |||||||
| 114972363 | 11497236 | 10 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | COURSE B: 5MG/M2 PO BID ON DAYS 1-5 | U | 0 | 5 | MG/M**2 | |||||||
| 114972363 | 11497236 | 11 | SS | VP-16 | ETOPOSIDE | 1 | Intravenous (not otherwise specified) | COURSE A: 100 MG/M2, OVER 2 HOURS ON DAYS 4 AND 5 | U | 0 | 100 | MG/M**2 | |||||||
| 114972363 | 11497236 | 12 | C | CYTARABINE. | CYTARABINE | 1 | Intrathecal | PROPHASE: 15-24MG ON DAY 1 | 0 | ||||||||||
| 114972363 | 11497236 | 13 | C | CYTARABINE. | CYTARABINE | 1 | Intravenous (not otherwise specified) | COURSE A: 150 MG/M2, OVER 1-30 MINUTES Q12 HOURS ON DAYS 4 AND 5 | 0 | 150 | MG/M**2 | ||||||||
| 114972363 | 11497236 | 14 | C | HYDROCORTISONE. | HYDROCORTISONE | 1 | Intrathecal | PROPHASE: 7.5-12 MG ON DAY 1 | 0 | ||||||||||
| 114972363 | 11497236 | 15 | C | IFOSFAMIDE. | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | COURSE A: 800 MG/M2, OVER 60 MINUTES ON DAYS 1-5 | 0 | 800 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 114972363 | 11497236 | 1 | Anaplastic large cell lymphoma T- and null-cell types |
| 114972363 | 11497236 | 2 | Anaplastic large cell lymphoma T- and null-cell types |
| 114972363 | 11497236 | 3 | Anaplastic large cell lymphoma T- and null-cell types |
| 114972363 | 11497236 | 6 | Anaplastic large cell lymphoma T- and null-cell types |
| 114972363 | 11497236 | 8 | Anaplastic large cell lymphoma T- and null-cell types |
| 114972363 | 11497236 | 11 | Anaplastic large cell lymphoma T- and null-cell types |
| 114972363 | 11497236 | 12 | Anaplastic large cell lymphoma T- and null-cell types |
| 114972363 | 11497236 | 14 | Anaplastic large cell lymphoma T- and null-cell types |
| 114972363 | 11497236 | 15 | Anaplastic large cell lymphoma T- and null-cell types |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 114972363 | 11497236 | OT |
| 114972363 | 11497236 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 114972363 | 11497236 | Anaemia | |
| 114972363 | 11497236 | Hypokalaemia | |
| 114972363 | 11497236 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |